Emergent Biosolutions, Inc. (EBS) News
Filter EBS News Items
EBS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EBS News Highlights
- For EBS, its 30 day story count is now at 10.
- Over the past 5 days, the trend for EBS's stories per day has been choppy and unclear. It has oscillated between 2 and 4.
- LI, SKIN and UL are the most mentioned tickers in articles about EBS.
Latest EBS News From Around the Web
Below are the latest news stories about EMERGENT BIOSOLUTIONS INC that investors may wish to consider to help them evaluate EBS as an investment opportunity.
U.S. FDA panel to review Emergent's OTC opioid overdose drugThe U.S. health regulator said on Tuesday its advisory panel will meet on Feb. 15 to review Emergent Biosolutions Inc's over-the-counter (OTC) nasal spray to treat suspected opioid overdoses. Emergent is seeking the Food and Drug Administration's (FDA)approval for the prescription-free sale of Narcan, its nasal spray form of the drug naloxone. Narcan is already cleared for the treatment of opioid overdose in the country. |
Emergent (EBS) to Start Restructuring Plan, Lays Off 5% WorkforceOnce this restructuring activity is completed, Emergent BioSolutions (EBS) expects to result in annualized savings of over $60 million. It also slightly raised its total revenue guidance for 2022. |
Emergent BioSolutions initiates layoffs, leadership and structural changes to cut costsEmergent BioSolutions Inc. is reshuffling leadership, consolidating certain functions and laying off about 5% of its workers in a bid to cut costs and focus on key business units. The Gaithersburg company said Monday it’s initiating an “organizational restructuring plan” that will position it to focus on its commercial and medical countermeasures products — its drugs and vaccines that protect against public health threats — as well as its contract development and manufacturing services. The changes involve eliminating 132 positions and consolidating its research, product development and clinical teams into a new function dubbed Science and Development, or S&D. A company spokesperson confirmed Monday to the Washington Business Journal that the layoffs will affect “a variety of roles,... |
Emergent BioSolutions to cut 5% of its workforce in reorganization effortEmergent BioSolutions Inc. is cutting 132 jobs, or approximately 5% of its workforce in a reorganization that the company says will sharpen its strategic focus on core businesses. The biotech described its core businesses as medical countermeasures and commercial products, including NARCAN nasal spray, as well as contract development and manufacturing services. As part of the reorganization, Emergent's newly-created Science & Development function is uniting research, product development, and cli |
UPDATE 1-Emergent BioSolutions to reduce workforce by about 5%Contract manufacturer Emergent BioSolutions Inc said on Monday it will reduce its workforce by about 5%, or 132 roles, and do away with the positions of chief people officer, as well as chief strategy and development officer. Emergent expects to incur charges of about $9 million to $11 million in the first quarter of 2023. In June, Johnson & Johnson had formally informed Emergent of its decision to terminate its deal with the contract manufacturer to make COVID-19 vaccines for the drugmaker. |
Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic FocusAnnounces Preliminary 2022 Financial Results GAITHERSBURG, Md., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced a sharpened strategic focus on protecting and enhancing life through its core businesses, consisting of medical countermeasures (MCM) and commercial products, including NARCAN® (naloxone HCl) Nasal Spray, as well as contract development and manufacturing (CDMO) services. Strategic developments include: The appointment of Paul Williams, Emergent’s cur |
Emergent BioSolutions gets ~$380M military contract for skin decontamination lotion kits
|
Emergent BioSolutions gets new Defense Department contract, shares rise 13%Shares of Emergent BioSolutions Inc. were higher in Thursday's after-hours market, following news the company received a contract to supply reactive skin decontamination lotion kits to the U.S. military. |
Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of DefenseGAITHERSBURG, Md., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity procurement contract with a maximum value up to $379.6 million to supply RSDL® (Reactive Skin Decontamination Lotion Kit) for use by all branches of the U.S. military. Emergent’s Canadian Subsidiary will serve as the sole subcontractor to deploy RSDL® to the U.S. Department of Defense (DoD) through a new contract award to the Ca |
Shareholders in Emergent BioSolutions (NYSE:EBS) are in the red if they invested three years agoAs every investor would know, not every swing hits the sweet spot. But you have a problem if you face massive losses... |